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ABSTRACT

The invention relates to the use of nicotinic acid alkyl esters,
especially myristyl nicotinate, to inhibit side effects associated with retinoic acid therapy. Also a part of the invention
is a method for improving skin cell differentiation by administering the nicotinic acid alkyl ester in an amount sufficient
to increase expression of caspase 14 and filaggrin. Deficiencies in expression of these molecules can be treated in this
way as well.
7 Claims, No Drawings
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METHOD FOR ALLEVIATING SIDE
EFFECTS OF RETINOIC ACID THERAPY
AND/OR IMPROVING EFFICACY WITHOUT
INTERFERING WITH EFFICACY

eration in the basal and/or lower spinous layers of the
epidermis. Eichner, et al., Br J Dermatol 1996; 135: 687-95.
Retinoids also can lighten hyperpigmented skin, reduce
tyrosinase activity in cultured melanocytic cells (Hoa!, et al.,
Cancer Res 1982; 42: 5191-5; Kang, et al., Am J Clin
Dermatol 2005; 6: 245-53), inhibit proliferation and lipid
synthesis, and alter keratin expression in cultured human
sebocytes. Zouboulis, et al., J Invest Dermatol 1991; 96:
792-7. In the dermis, effects include increased fibroblast
proliferation (Varani, et al., supra), increased collagen production (Griffiths, et al., N Engl J Med 1993; 329: 530-5),
and reduced extracellular matrix degradation (Fisher and
Voorhees, supra).
The degradation of collagen in the dermis is a major factor
in the formation of skin wrinkles. Prolonged use of retinoic
acid significantly increases collagen matrix deposition in
dermal repair zones and this effect appears to be responsible
for the wrinkle reduction that accompanies retinoic acid
treatment of photodamaged skin. (Cho, et al., supra; Kang,
et al., supra).
While retinoic acid provides multiple benefits to photodamaged skin (Kang, et al., supra), it is frequently accompanied by significant skin irritation that limits compliance
with therapy. Lowe, et al., J Cosmet Laser Ther 2004; 6:
79-85. The most commonly reported retinoic acid treatmentrelated adverse effects are irritation, dryness, peeling, erythema, and a sensation of burning on the skin. Lowe, et al.,
supra. These side effects often result in discontinuation of
therapy.
Hence, a method to diminish or eliminate the side effects
associated with retinoic acid therapy is needed.
The mechanisms that lead to retinoid side effects are still
incompletely understood but retinoic acid therapy is known
to impair stratum comeum barrier function as assessed by
TEWL measurements. Tagami, et al., Br J Dermatol 1992;
127: 470-5. Barrier impairment has been attributed to retinoid-induced epidermal hyperplasia (Varani, et al., Arch
Dermatol Res 2003; 295: 255-62) and to alteration of the
terminal differentiation program (Fisher, et al., supra). Erythema, which reflects the production of epidermal cytokines
such as IL-1, may result from retinoid-stimulated keratinocyte proliferation directly or as a consequence of epidermal
barrier impairment. Wood, et al., J Invest Dermatol 1996;
106: 397-403; Blanton, etal.,ProcNatlAcadSci USA 1989;
86: 1273-7. Retinoid-induced stratum corneum compaction
(Olsen, et al., supra; Machtinger, et al., supra) is likely
related to barrier impairment as stratum comeum thickness
is a major determinant of barrier function (Ya-Xian, et al.,
Arch Dermatol Res 1999; 291: 555-9; de Jongh, et al., Br J
Dermatol 2006; 154: 651-7).
Niacin derivatives have been developed for optimal topical delivery of nicotinic acid to skin (Jacobson, et al.,
Developing Topical Prodrugs for Skin Cancer Prevention.
In: Fundamentals of Cancer Prevention (Alberts D S, Hess,
Lisa M., ed). Berlin Heidelberg: Springer-Verlag, 2005:
139-60) and have been shown to enhance epidermal differentiation in photodamaged skin, resulting in increased stratum comeum and epidermal thickness and enhanced skin
barrier function as assessed by decreased rates of TEWL.
Jacobson, et al., Experimental Dermatology, in press. Niacin
derivatives are also described in U.S. Pat. Nos. 6,337,065,
6,677,361, 6,750,234 and 6,924,299, each of which is incorporated by reference in its entirety.
One such niacin derivative is myristyl nicotinate, which
was developed for optimal topical delivery of nicotinic acid
to skin. Myristyl nicotinate has been shown to enhance
epidermal differentiation in photodamaged skin, resulting in
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RELATED APPLICATION
This application is a 371 application from PCT/US2008/
002605 filed Feb. 27, 2008, which claims priority of Provisional application Ser. No. 60/903,937 filed Feb. 28, 2007,
and incorporated by reference in their entirety.
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FIELD OF THE INVENTION
The invention relates to the use of niacin derivatives to
alleviate side effects resulting from retinoic acid therapy
and/or improving efficacy without interfering with efficacy
of retinoic acid therapy. More particularly, niacin derivatives, such as straight chain nicotinic acid alkyl esters,
myristyl nicotinate in particular, alleviate side effects from
retinoic acid therapy such as, but not exclusively, tightness/
dryness, stinging, burning, and tingling, as discussed infra.
Also a feature of the invention is the improvement of skin
cell differentiation by increasing expression of caspase-14
and filaggrin.
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BACKGROUND OF THE INVENTION
Retinoids, the natural metabolites and synthetic analogues
of vitamin A (retinal), are important regulators of skin
function. Fisher, et al., FasebJ 1996; 10: 1002-13. All-transretinoic acid (vitamin A acid), the major naturally occurring
biologically active retinoid, has been a focus of research for
possible use in topical treatments for photodamaged skin,
for many years. In 1986, it was reported that retinoic acid
could produce smoother, less wrinkled, and less pigmented
skin after a few months of treatment. Kligman et al., J Am
Acad Dermatol 1986; 15: 836-59.
Long-term exposure of skin to sunlight leads to a series of
progressive changes that range from loss of skin texture and
tone to thinning of the epidermis and stratum comeum
(Gilchrest, Br J Dermatol 1996; 135: 867-75), flattening of
the dermal-epidermal junction (Benedetto, Clin Dermatol
1998; 16: 129-3 9), generation of areas of hyperpigmentation
(Gilchrest, supra), wrinkles, and accumulation of keratinocytes with atypical morphology that are likely precursors to
actinic keratoses and non melanoma skin cancers (Cho, et
al., J Am Acad Dermatol 2005; 53: 769-74; Lober, et al., J
Am Acad Dermatol 2000; 43: 881-2). Photodamage occurs
in both the epidermal and dermal compartments, where
retinoids have been shown to have prominent pharmacological effects. Gendimenico, et al., Skin Pharmacol l 993; 6
Suppl 1: 24-34; Varani, et al., J Invest Dermatol 2000; 114:
480-6; Cho, et al., supra. In the epidermis of photodamaged
skin, long-term topical retinoid therapy results in dose
dependent increases in epidermal and granular layer thickness, stratum corneum compaction, decreased melanin content and improvement of epidermal atypia. Fisher et al.,
supra; Cho, et al., supra; Olsen, et al., J Am Acad Dermatol
1992; 26: 215-24; Machtinger, et al., Br J Dermatol 2004;
151: 1245-52. In keratinocytes, retinoids induce proliferation, presumably mediated by epidermal growth factor
receptor activation resulting in epidermal hyperplasia. Rittie, et al., J Invest Dermatol 2006; 126: 732-9.
Retinoic acid induced expression of keratins K6, Kl 6, and
Kl 7, which are commonly expressed in hyperproliferative
epidermal cells, indicates that retinoids increase cell prolif-
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increased stratum comeum and epidermal thickness and
enhanced skin barrier function as assessed by decreased
rates ofTEWL. Jacobson, et al., Experimental Dermatology,
in press.
Hence, it is an object of the present invention to treat the
side effects caused by retinoic acid therapy with niacin
derivatives. A further feature of the invention is the improvement of skin cell differentiation via use of these niacin
derivatives.

bility that stratum corneum compaction is one factor
involved in the barrier impairment associated with retinoic
acid therapy.
Accordingly, periorbital biopsy samples obtained from
study subjects were evaluated for stratum corneum thickness. A board certified dermatologist collected a 2-mm
punch biopsy from the right or left side of the face as
determined by a randomization design of 7 randomly
selected subjects from each group at baseline and after 12
weeks of treatment. The punch biopsies were formalin-fixed,
embedded in paraffin, cut into 5 µm cross-sections, mounted
on slides, and stained with hematoxylin-eosin (H&E).
Histological images were taken of the H&E stained cross
sections with an Olympus inverted stage microscope using
a !Ox by 0.45 Apochromat objective and a Nikon digital
CCD camera. ImageJ image analysis software (NIH) was
used to examine the images and perform measurements.
Suprapapillary epidermal thickness (as measured from the
top of the dermal papilla to the top of the granular layer) and
stratum comeum thickness (as measured from the top of the
granular layer to the top of the stratum corneum) were
measured. For each specimen, five different sites were
measured and the average was calculated.
At baseline, the mean stratum comeum thickness value of
the placebo/MN+RA group was slightly higher than the
placebo/placebo+ RA group, although the difference was not
statistically significant. The mean stratum comeum thickness of the MN/MN+RA group, which had been treated for
one month with 5% myristyl nicotinate, was higher than the
other two groups, although the difference did not reach
statistical significance at p<0.05. However, previous studies
have shown that treatment of photodamaged skin with 5%
myristyl nicotinate for 3 months results in an increase in
stratum comeum thickness of more than 50%. Thus the
approximately 11 % higher mean value of MN/MN+RA
group compared to the mean values of the other groups
agrees with the known effect of myristyl nicotinate.
During the 12 weeks of retinoic acid therapy, the placebo/
placebo+RA group experienced a reduction in stratum corneum thickness of approximately 24% (p=0.006 vs. baseline), while concurrent use of myristyl nicotinate and
retinoic acid did not result in a decrease in stratum comeum
thickness. The difference in mean stratum comeum thickness between the placebo/placebo+RA and placebo/MN+
RA group at 12 weeks of therapy was highly statistically
significant (p=0.005). The difference between the MN/MN+
RA group and the placebo/placebo+RA group at 12 weeks
also was highly statistically significant (p=0.003). These
results show that concurrent or prior and concurrent use of
myristyl nicotinate mitigates stratum comeum compaction
associated with retinoic acid therapy.
Determination of rates of TEWL provides a non-invasive
assessment of relative skin barrier function. Hence, TEWL
measurements were taken from the faces of study subjects
and used as a surrogate marker of barrier function to
compare placebo and myristyl nicotinate treated groups. For
the TEWL measurements, the instruments required a specified temperature and humidity range for optimal function,
thus subjects were required to equilibrate to ambient conditions for at least 20 min prior to measurements. Temperature was maintained between 66 and 72° F. and relative
humidity maintained between 15 and 55%. A computerlinked Dermalab instrument was used to measure TEWL at
two points above the skin surface on the right cheeks of
study subjects and the rate of water loss was calculated.
Each TEWL measurement was averaged over a one-min
measurement period.
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DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS
EXAMPLE 1
15

A clinical study was conducted to examined the combined
use of retinoic acid therapy with myristyl nicotinate (MN),
a lipophilic derivative of niacin that enhances skin barrier
function, in subjects with mild to moderate facial photodamage.
All subjects selected for the study were female, between
the ages of 30 and 60, with a score of I to IV on the
Fitzpatrick Skin Classification, mild to moderate photodamaged skin as defined by a modified Glogau Classification of
I to II, and with presence of dyschromia on the face as
determined by a woods light visual scan.
The subjects were randomly assigned to one of three
groups of 20 subjects each. One month prior to the initiation
ofretinoic acid therapy, one of the groups (group 3) began
to apply to the entire face, both night and morning, a
formulation containing 5% myristyl nicotinate. Groups 1
and 2 applied, in the same manner, a placebo formulation in
which myristyl myristate replaced myristyl nicotinate. Upon
initiation of retinoic acid therapy (baseline), group 1 (placebo/placebo+RA) continued to use the placebo formulation
as above, group 2 (placebo/MN+RA) initiated use of the 5%
myristyl nicotinate formulation and group 3 (MN/MN+RA)
continued to use the 5% myristyl nicotinate formulation.
Retinoic acid therapy involved a 0.025% concentration of
the drug applied at night, immediately following application
of the placebo or myristyl nicotinate containing formulations. This strength of retinoic acid was chosen for this study
as the subjects had mild to moderate photodamage.
Subjects also were provided with mild liquid cleansers
and sunscreen to use for facial cleansing and sun protection
during the entire course of the study. Subjects applied the
assigned test moisturizers [myristyl nicotinate (5%) or a
placebo that contained myristyl myristrate replacing myristyl nicotinate] to their entire face twice per day after
cleansing. During the usage phase of the study, subjects
applied the retinoic acid formulation (0.025%) to their face
after test moisturizer application once per day in the evening.
The effects of the 5% myristyl nicotinate formulation on
surrogate markers of skin barrier function, clinical and
sensory irritation, and clinical efficacy associated with retinoic acid use were evaluated. Periorbital skin biopsy
samples were evaluated for stratum corneum thickness and
rates oftransepidermal water loss (TEWL) were determined
as surrogate measures of barrier function, tolerability was
evaluated by clinical grading, and efficacy was assessed by
clinical grading, patient self-assessment, and analysis of
biopsy samples for epidermal thickness.
Stratum corneum compaction typically accompanies retinoic acid therapy and studies relating increased barrier
function to an increased stratum corneum thickness (YaXian, et al., supra; de Jongh, et al., supra) raise the possi-
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The rates ofTEWL increased in the placebo/placebo+RA
group by during the 12 week period approximately 45%, a
value that was highly statistically significant (p<0.0001).
The mean rates of TEWL also increased in the placebo/
MN+RA and MN/MN+RA groups, although the changes
from baseline for these groups were not statistically significant. The difference between the placebo/placebo+RA and
MN/MN+RAgroups at 12 weeks (p=0.056) demonstrated a
strong trend towards statistical significance.
These results indicate that concurrent use of myristyl
nicotinate mitigates barrier impairment and that prior use
plus concurrent use provides greater barrier protection than
concurrent use alone.
Clinical Grading
In order to assess both the tolerability and efficacy of
retinoic acid therapy, subjects also were clinically graded on
the right and/or left side of the face for efficacy/performance
parameters and irritation/safety parameters at baseline, and
weeks 2, 4, 8, and 12.
The most severe parameters of tolerability such as sealing/peeling and degree of erythema were graded on 3-point
clinical scale at weeks 2, 4, 8, and 12, and mean values were
determined. The frequency of less severe parameters of
tolerability typical of retinoic acid therapy (including tightness/dryness, stinging, burning, and tingling) was also
evaluated.
The degree of scaling/peeling was very low in all groups
and the degree of erythema also was relatively low, indicating an overall high degree of tolerance of the 0.025%
concentration of retinoic acid and/or the regular use of a
moisturizer twice per day prior to and during therapy. There
were no statistically significant differences between placebo
and myristyl nicotinate groups in either parameter, although
the grading of erythema was consistently slightly higher in
the myristyl nicotinate treated subjects.
Despite the low levels of scaling/peeling or erythema, a
significant frequency of less severe but commonly encountered side effects of retinoic acid were observed in the study.
For these tolerability parameters, a consistent pattern was
observed as concurrent use ofmyristyl nicotinate decreased
the frequency of tightness/dryness, stinging, and burning,
and prior and concurrent myristyl nicotinate use further
reduced the frequency of each of these parameters. Although
the frequency of tingling reported was quite low (2% ), the
incidence of this side effect was reduced to zero for the
MN/MN+RA group.
In addition to the clinical grading, study subjects completed self-assessment questionnaires that solicited information related to tolerability of the therapy. These self-assessments paralleled the clinical grading in all cases where the
same parameter was assessed. In total, the results show that
use of myristyl nicotinate improved the tolerability of retinoic acid therapy.
Expert clinical grading, patient self-assessment, and
analysis of biopsy samples for epidermal thickness were also
used to examine the effect of myristyl nicotinate on the
efficacy of retinoic acid therapy.
Clinical grading involved evaluation of dyschromia, fine
lines, shallow wrinkles, tactile roughness, and temple laxity
as a function of treatment time (at weeks 2, 4, 8, and 12).
Despite some differences in the degree of initial photodamage between the groups, similar rates of improvement for all
three groups were observed for dyschromia, fine lines, and
shallow wrinkles. This also was observed for tactile roughness although scores for the MN/MN+RAgroup consistently
showed greater improvement from weeks 4 to 12. Grading
of temple laxity showed a statistically significant greater

improvement (p=0.02) at 12 weeks in the MN/MN+RA
group compared to the placebo/placebo+RA and a trend for
greater improvement for the placebo/MN+RA compared to
placebo/placebo+RA was observed that did not reach statistical significance at p<0.05.
Study subjects also completed a self-assessment questionnaire at the completion of the study that related to their
assessment of efficacy. This questionnaire requested study
subjects to respond to questions with one of 5 choices
(Strongly agree, agree, neither agree nor disagree, disagree,
strongly disagree). In no case did subjects in the groups
using myristyl nicotinate rate efficacy lower than subjects in
the placebo/placebo+RA group and in four of the five
questions a greater percentage of study subjects using myristyl nicotinate perceived improved efficacy compared to the
placebo group. These results indicate that concurrent or prior
and concurrent use of myristyl nicotinate did not interfere
with retinoic acid efficacy and by some parameters resulted
in improved efficacy.
Since long term retinoid therapy is associated with an
increase in epidermal thickness, changes in epidermal thickness in each of the groups over the 12-week course of the
retinoic acid therapy were also assessed. The mean values
for the placebo/placebo+RA, placebo/MN+RA, and
MN/MN+RA groups at the baseline were 37.9, 38.8, and
39.3 µm, respectively. The mean epidermal thickness of the
group receiving retinoic acid and the placebo cream
decreased by approximately 5% over the 12 week study. The
epidermal thickness of the group concurrently receiving
myristyl nicotinate increased by approximately 3% and the
group receiving myristyl nicotinate prior/concurrent with
retinoic acid increased by approximately 10%. The difference between the placebo/placebo+RA and MN/MN+RA
groups at 12 weeks was statistically significant (p=0.0007)
while the difference between placebo/placebo and placebo/
MN+RA groups showed a trend but did not reach statistical
significance at p<0.05. The difference between the placebo/
MN+RAand MN/MN+RAgroups at 12 weeks also reached
statistical significance (p=0.05).
The results of clinical grading, self-assessment and epidermal thickness determinations indicate that the efficacy of
retinoic acid therapy was not negatively affected by myristyl
nicotinate. Further, the results indicate that the use of
myristyl nicotinate increased efficacy of retinoic acid
therapy.
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Caspase-14 has been shown to be a unique protease which
controls maturation of the epidermis. This control results
from proteolytic processing of filaggrin, a protein that is
recognized as being involved in late stages of skin cell
differentiation. The products of the action of caspase-14 on
filaggrin prevent UVB photodamage, as well as water loss.
See, e.g., Nicotera, et al., Nature Cell Biology 9:621-622
(2007); Denecker, et al., Nature Cell Biology 9:666-674
(2007), both of which are incorporated by reference.
Rend!, et al., J. Investigative Dermatol 119: 1150-1155
(2002), incorporated by reference, have shown that retinoids
down regulate caspase 14.
The interrelationships amongst caspase 14, filaggrin, and
retinoids suggested that they might be impacted by myristyl
nicotinate.
To investigate this, the levels of expression of both
caspase 14 and filaggrin were investigated in the groups of
subjects referred to supra, (i.e., subjects who received placebo alone for one month, then placebo plus retinoic acid,

US 9,642,845 B2
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and those who received placebo only for one month and then
myristyl nicotinate and retinoic acid during the treatment
phase.
An average increase of 5% in caspase 14 expression was
found in subjects who received placebo plus retinoic acid for
3 months, while subjects who received placebo, retinoic acid
and myristyl nicotinate for 3 months showed a 24% increase
in caspase 14 expression over the same period.
With respect to filaggrin expression, subjects receiving
placebo, myristyl nicotinate and retinoic acid showed an
average increase of 13%, while subjects not treated with
myristyl nicotinate showed no change.
These results clearly establish a link between myristyl
nicotinate and the beneficial effects of the interplay of
caspase 14 and filaggrin, on skin cell differentiation, as
discussed supra.
The foregoing description sets forth various features of
the invention which include, inter alia, a method for alleviating a side effect of retinoic acid therapy and/or improving
efficacy and/or not interfering with efficacy in a patient
receiving said therapy, by administering an amount of a
nicotinic acid derivative, such as a nicotinic acid ester.
Preferably, this is a nicotinic acid alkyl ester. Especially
preferred are nicotinic acid alkyl esters, where the ester
moiety contains from 10-18 carbon atoms.
The mode by which the nicotinic acid ester is administered to the subject may vary. Oral, time release, intravenous, intradermal, and other forms of administration are
contemplated, as is topical administration.
Topical administration refers to the application of a nicotinic acid ester to the external surface of the skin or the
mucous membranes (including the surface membranes of the
nose, lungs and mouth), such that the nicotinic acid ester
crosses the external surface of the skin or mucous membrane
and enters the underlying tissues. In the preferred form, the
nicotinic acid ester is applied topically for dermal or transdermal delivery of nicotinic acid. Transdermal delivery
refers to the diffusion of a nicotinic acid ester across the
barrier of the skin after which it is bioconverted to nicotinic
acid by skin esterases. Absorption through intact skin can be
enhanced by placing the nicotinic acid ester in an oily
vehicle before application to the skin (a process known as
inunction). Passive topical administration may consist of
applying the nicotinic acid ester directly to the treatment site
in combination with emollients or penetration enhancers.
Such topical administration is particularly preferred and
may be via a cream, lotion, liquid, aerosol, body wash,
mouthwash, toothpaste, gavage, or other form of topical

administration. For example, in the case of timed released
application, "patches," such as the type used in timed release
of nicotine, bandages, wraps, and so forth may be employed.
The nicotinic acid ester is administered in an amount
sufficient to alleviate a side effect of retinoic acid therapy.
The dose used can and will vary.
Another feature of the invention is the a method for
improving mature skin cell differentiation, by administering
an amount of a nicotinic acid alkyl ester, as described supra,
in an amount sufficient to increase expression of caspase 14
and filaggrin. Increased expression of these two molecules
lead to increased interactions, which in turn leads to
improvements in skin cell differentiation. Myristyl nicotinate is especially preferred.
Other aspects of the invention will be clear to the skilled
artisan and need not be set forth herein. The terms and
expressions which have been employed are used as terms of
description and not of limitation, and there is no intention in
the use of such terms and expressions of excluding any
equivalents of the features shown and described or portions
thereof, it being recognized that various modifications are
possible within the scope of the invention.
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The invention claimed is:
1. A method for alleviating or preventing a side effect
caused by retinoic acid without interfering with efficacy of
said retinoic acid, comprising administering an amount of a
nicotinic acid alkyl ester selected from the group consisting
of myristyl nicotinate and palmityl nicotinate sufficient to
alleviate or to prevent said side effect, to a subject for at least
one month prior to said subject receiving, or while said
subject is receiving, said retinoic acid.
2. The method of claim 1 wherein said nicotinic acid alkyl
ester is administered topically.
3. The method of claim 1, wherein said nicotinic acid
alkyl ester is administered by dermal or transdermal delivery.
4. The method of claim 1, comprising administering said
nicotinic acid alkyl ester concurrently with said retinoic
acid.
5. The method of claim 1, further comprising administering said nicotinic acid alkyl ester to said subject for at least
one month prior to administration of said retinoic acid.
6. The method of claim 1, wherein said subject is a
mammal.
7. The method of claim 6 wherein said mammal is a
human.
*

*

*

*

*

